Business
Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Carmen Bozic, M.D., has been appointed as the company’s
About this update from Vertex Pharmaceuticals Incorporated
[{"type":"text","content":" BOSTON--(BUSINESS WIRE)--\nVertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Carmen Bozic, M.D., has been appointed as the company’s Executive Vice President, Global Medicines Development and Medical Affairs. Dr. Bozic will assume the additional role of Chief Medical Officer on April 1, 2020 when Reshma Kewalramani, M.D., the company’s current Chief Medical Officer, becomes President and Chief Executive Officer of Vertex. Dr. Bozic has served as Senior Vice President and Head of Global Clinical Development since May of this year.\n\n\nVertex also announced the appointment of Nia Tatsis, Ph.D., currently Vertex’s Senior Vice President, Global Regulatory Affairs, as Senior Vice President, Chief Regulatory Officer, effective immediately.\n\n\n“The addition of Carmen and Nia to Vertex’s executive team further strengthens our leadership ranks as we work towards completing our CF journey and bringing new therapies into the clinic in a variety of new disease areas,” said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex.\n\n\nDr. Bozic received her M.D. and completed her residency in Internal medicine at McGill University in Montreal, Canada, and then completed a fellowship in Pulmonary and Critical Care Medicine at Brigham and Women’s Hospital in Boston. Since joining Vertex, she has been leading Clinical Development of the company’s cystic fibrosis and alpha-1 antitrypsin deficiency programs, as well as leading Clinical Operations across the pipeline, among other areas. Prior to joining Vertex, Dr. Bozic spent more than 20 years at Biogen, including as Senior Vice President, Global Development. During her tenure at Biogen, she led multiple functions, including Global Clinical Development, Safety, Preclinical Safety, Regulatory, Clinical Operations and Biometrics.\n\n\n“I am thrilled to take on the leadership of Vertex’s talented Global Medicines Development and Medical Affairs team at such an exciting time for the company,” said Dr. Bozic. “Vertex advanced its cystic fibrosis portfolio through the clinic with unprecedented speed and purpose, and now has seven potential therapies in the clinic with the opportunity to transform the treatment of patients with other serious diseases.”\n\n\nDr. Tatsis received her Ph.D. in Cell and Molecular Biology from the University of Vermont...